The MHRA and CHM have published the April edition of Drug Safety Update. This edition advises healthcare professionals of the following:
- In patients taking atypical (second-generation) antipsychotics, weight, glucose, and lipid levels should be monitored and managed
- Tigecycline▼ has been shown to be associated with increased mortality in clinical trials and should be prescribed only when other antibiotics are unsuitable
- Stavudine should be used only when there are no appropriate alternatives, and then only for the shortest possible time. This is due to an increased risk of potentially severe adverse effects compared with alternative HIV treatments.
- Prescribers of Vivaglobin® are asked to be vigilant for signs of arterial or venous thromboembolism due to the rare risk of associated thromboembolic events. Where possible, prescribers are advised to use alternative appropriate therapy for patients with risk factors for thromboembolism.
via npc.nhs.uk
No comments:
Post a Comment